Rashmi K. Murthy, Ankur Varma, Priyankana Mishra, Kenneth R. Hess, Elliana Young, James L. Murray, Kimberly H. Koenig, Stacy L. Moulder, Amal Melhem-Bertrandt, Sharon H. Giordano, Daniel Booser, Vicente Valero, Gabriel N. Hortobagyi and Francisco J. Esteva Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer Cancer 120
Article first published online: 26 MAR 2014 | DOI: 10.1002/cncr.28689
Trastuzumab-naive patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer have superior clinical outcomes to those patients treated with trastuzumab-based therapy. Prior trastuzumab exposure should be considered in the design of clinical trials and sequencing of HER2-targeted therapies.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.